Clinical potential of SLAMF7 antibodies – focus on elotuzumab in multiple myeloma

Clinical potential of SLAMF7 antibodies – focus on elotuzumab in multiple myeloma

Reed Friend, Manisha Bhutani, Peter M Voorhees, Saad Z Usmani Department of Hematologic Oncology & Blood Disorders, Levine Cancer Institute, Carolinas Healthcare System, UNC School of Medicine, Charlotte, NC, USA Abstract: Elotuzumab is one of the first monoclonal antibodies to be approved...

Full description

Bibliographic Details
Main Authors: Friend R, Bhutani M, Voorhees PM, Usmani SZ
Format: Article
Language:English
Published: Dove Medical Press 2017-03-01
Series:Drug Design, Development and Therapy
Subjects:
multiple myeloma
relapsed
refractory
treatment
elotuzumab
SLAMF7
CS1
Online Access:https://www.dovepress.com/clinical-potential-of-slamf7-antibodies-ndash-focus-on-elotuzumab-in-m-peer-reviewed-article-DDDT

Internet

https://www.dovepress.com/clinical-potential-of-slamf7-antibodies-ndash-focus-on-elotuzumab-in-m-peer-reviewed-article-DDDT

Similar Items